Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-085143
Filing Date
2025-06-12
Accepted
2025-06-12 08:08:08
Documents
75
Period of Report
2025-04-30

Document Format Files

Seq Description Document Type Size
1 10-Q engn-20250430.htm   iXBRL 10-Q 2254423
2 EX-10.2 engn-ex10_2.htm EX-10.2 149704
3 EX-10.3 engn-ex10_3.htm EX-10.3 147927
4 EX-31.1 engn-ex31_1.htm EX-31.1 22655
5 EX-31.2 engn-ex31_2.htm EX-31.2 22323
6 EX-32.1 engn-ex32_1.htm EX-32.1 11590
7 EX-32.2 engn-ex32_2.htm EX-32.2 11593
  Complete submission text file 0000950170-25-085143.txt   10356509

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20250430.xsd EX-101.SCH 1720352
78 EXTRACTED XBRL INSTANCE DOCUMENT engn-20250430_htm.xml XML 1848164
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-41854 | Film No.: 251041710
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)